• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing

Should I Get Back in DocuSign?

The quarter's results are fantastic, and the 'accelerating growth' is quite impressive to say the least.
By STEPHEN GUILFOYLE
Dec 04, 2020 | 10:13 AM EST
Stocks quotes in this article: DOCU

Another winner. To be more precise, another "work from home", or "work from anywhere" winner. DocuSign (DOCU) reported the firm's third quarter financial results on Thursday evening. The results are fantastic. The growth, or shall we say the "accelerating growth", is quite impressive to say the least. Yes, this was one of the names I gave you early in the pandemic as a likely winner. That was easy. Obviously, the need to sign documents remotely was going to explode as employees scattered. The firm does more than just e-signatures too, from contract management to remote notary services in states that allow it.

That said, I have now been long out of the stock after shaving my position each time a new target price had been overrun. The question now becomes... "Should I get back in?" Maybe I should be satisfied that I did have a nice trade. For those who have never played the name, is it too late now? Let's dig in.

The Quarter Behind

For the period reported, DocuSign posted adjusted EPS of $0.22, well above the consensus view that was in between a dime and 15 cents. Revenues landed at $382.92 million, beating expectations and good for year over year growth of 53.5%. By the way, this was the third quarter of accelerating year over year growth after growth had appeared to have stabilized prior to the pandemic just below the 40%-ish level. It goes well beyond the headline numbers. Subscription revenue screamed 54% higher, Professional services a mere 43%. Billings roared in at $440 million for the quarter, up 63%,and just obliterating expectations.

Basically, DocuSign made better than good contact on every pitch they saw. About the only place that the firm came in flat was adjusted gross margin where they "merely" met expectations of 79%. Cash from operations of $57.4 million, produced free cash flow of $38.1 million, which left the firm with a net cash position of $675.6 million. Not too shabby at all.

Moving Along

For the current quarter (Q4), DocuSign is taking revenue guidance up to $404 million to $408 million, from a consensus (17 sell-side analysts) of roughly $389 million. The firm now guides subscription revenue to rise to $384 million to $388 million, and billings to land in between $512 million and $522 million. For the full year, the firm now sees total revenues at $1.426 billion to $1.43 billion, which is above the $1.39 billion that Wall Street had in mind. Full year subscriptions are seen rising to $1.355 billion to $1.359 billion, and full year billings to $1.7 billion to $1.71 billion. Most interestingly, the firm guides adjusted gross margin toward the 78% to 80% range that it always seems to be in. Same as it ever was.

Wall Street

The sell-side has been very active this morning in reaction to these earnings and this guidance. I see at least seven so far. Of those, six are rated at five stars by Tip Ranks, including such rock stars as Dan Ives at Wedbush, Walter Pritchard at Citigroup, and Alex Zukin at RBC Capital. All six were positive in their commentary. All reiterated "buy" ratings or their firm's equivalent. Most increased price targets. Of these six, there are six "buys", with an average target price of $288, including a high of $325 (Zukin), and a low of $270 (Ives).

The Chart

Outside of the odd spike that occurred just ahead of Q2 earnings in early September, this stock had settled into something of a basing period of consolidation. Resistance throughout this period has been staunch at $246. Obviously, after indeed running into some interference at that spot overnight, the shares have kicked that door open during the regular session. Holding above $246, which is now the pivot is key. We go into the weekend with a close above that level, and technically... $295 becomes very possible. If I am long the shares (I am not), I would be moving my panic point up to $220 (the 50 day SMA) at this point.

I am thinking about writing the $245 puts expiring this afternoon, while they are still trading above a buck, just an FYI, but now I have to wait until publication because I thought about it out loud. We'll see.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoyle had no position in the securities mentioned.

TAGS: Earnings | Investing | Stocks | Technical Analysis | Trading | Commercial & Professional Services | Consumer Services

More from Investing

In a Week Full of Surprises, This Was the Market's Biggest

James "Rev Shark" DePorre
Feb 3, 2023 4:42 PM EST

We had the Fed's rate decision, jobs numbers, and mega-cap tech earnings land. But here's what was the wildest action.

3 High-Yield REITs for Safe Dividend Income

Bob Ciura
Feb 3, 2023 2:31 PM EST

These names have joined the ranks of the world's most elite dividend growth companies as Dividend Aristocrats and/or Dividend Kings.

The Charts Just Don't Give Much Affirmation on Affirm Ahead of Earnings

Bruce Kamich
Feb 3, 2023 1:54 PM EST

Here's the picture we see from this payment company.

I Found a Good-Looking Arrowhead in This Biotech ETF

Bruce Kamich
Feb 3, 2023 12:50 PM EST

Let's review the charts of XBI, the SPDR S&P Biotech ETF.

Holy Fed, Batman! FAANG Has a Major Toothache!

Jim Collins
Feb 3, 2023 12:23 PM EST

Here's why the markets are sounding a lot like the campy 'Batman' show -- and how to make sure you don't succumb to the market's Joker.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 02:58 PM EST REAL MONEY

    Sarge Guilfoyle Breaks Down the Jobs Report, Fed Policy and Stocks!

    Watch it here!
  • 11:35 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Trading an Irrational Market
  • 02:10 PM EST REAL MONEY

    Fed Rate Decision

    Fed Lifts Benchmark Rate by 25 Basis Points, Sees ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login